Browsing Category
Pharma Industry News
4722 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Why Seaport’s U.S. IPO filing matters now for neuropsychiatric drug development and biotech capital markets
Seaport Therapeutics has filed for a U.S. IPO. Read how its neuropsychiatry pipeline could test biotech investor appetite in 2026.
Why Abbott Laboratories (NYSE: ABT) faces more than a legal bill after $70m Chicago baby formula ruling
Abbott was ordered to pay $70 million in a Chicago baby formula case. Read what the NEC verdict could mean for litigation risk, strategy, and ABT stock.
ASCRS 2026 in Washington DC: What ophthalmologists need to know
ASCRS 2026 annual meeting runs April 10-13 in Washington DC. Full guide to the programme, key speakers, technology announcements, SightLine, and CME for anterior segment surgeons.
Why BeOne Medicines (ONC) just strengthened its China oncology play with Imdelltra approval
BeOne Medicines wins China approval for Amgen’s Imdelltra in lung cancer. Read why this matters for ONC, competition, and China oncology growth.
Why is Avalyn Pharma going public now, and what does it reveal about biotech risk appetite?
Avalyn Pharma has filed for a U.S. IPO to fund inhaled pulmonary fibrosis drugs. Read what the move signals for biotech markets and lung disease therapy.
What John M. Gay’s CFO appointment means for Pelthos Therapeutics (NYSE American: PTHS) and its next growth phase
Pelthos Therapeutics has named John M. Gay as CFO. Read what the move signals for Zelsuvmi growth, funding strategy, and Pelthos stock now.
Corcept Therapeutics (CORT) stock in focus as ROSELLA survival data strengthen Lifyorli launch in ovarian cancer
Corcept Therapeutics strengthened its Lifyorli launch with new ROSELLA survival data. Read what this means for CORT stock and ovarian cancer treatment.
Why acute stress disorder may become the next major neuroscience opportunity for BXCL501
Could BXCL501 open a major new neuroscience market in acute stress disorder? Read what this means for BioXcel Therapeutics and investors.
Why clinicians and pharma partners may be watching BioJet more closely after the latest data
Why clinicians and pharma partners may be watching BioJet more closely after the latest data. Read the full BNT executive analysis on what changes next.
Why platinum-resistant ovarian cancer remains a high-stakes proving ground for CDH6-targeted ADCs
Can SIM0505 change NextCure’s oncology outlook? Read why platinum-resistant ovarian cancer is the key test case for 2026.